GO:0005971 ribonucleoside-diphosphate reductase complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005971 describes the ribonucleoside-diphosphate reductase complex (RNR complex), the enzyme machine that converts ribonucleoside diphosphates into 2'-deoxyribonucleoside diphosphates, the building blocks of DNA.
• The complex is composed of 2-4 or more subunits, usually contains nonheme iron, and requires ATP for catalysis.
• RNR activity is essential for DNA replication and repair, and its inhibition or knockdown leads to replication stress and cell cycle arrest.
• The best-characterized subunits are the large B1 (nrdA) and small B2 (nrdB) proteins, which form active and inactive complexes in a regulated manner.
• RNR is a validated target in cancer and antiviral therapy, with gemcitabine and other nucleoside analogs acting on this complex.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of RNR subunit function in health and disease.
Description
The ribonucleoside-diphosphate reductase complex (GO:0005971) is a multi-subunit enzyme complex that catalyzes the rate-limiting step in the de novo synthesis of deoxyribonucleotides, converting ribonucleoside diphosphates to their 2'-deoxy counterparts. This reaction is essential for DNA replication and repair, making the complex a central node in cell proliferation and genome maintenance. The complex is found across all domains of life, from bacteriophage T4 to humans, and its subunits are highly conserved. In humans, the complex is a validated target for anticancer and antiviral therapies, as its inhibition depletes dNTP pools and induces replication stress. Understanding the structure, regulation, and function of the RNR complex is therefore critical for both basic biology and therapeutic development.
ribonucleoside-diphosphate reductase complex At A Glance
| GO ID | GO:0005971 |
|---|---|
| GO term | ribonucleoside-diphosphate reductase complex |
| Ontology | cellular_component |
| Synonym | ribonucleotide reductase complex, RNR complex |
| Major function | Catalyzes the conversion of ribonucleoside diphosphates to 2'-deoxyribonucleoside diphosphates, essential for DNA synthesis and repair. |
| Subunit composition | 2-4 or more subunits; typically includes large (B1) and small (B2) subunits. |
| Cofactors | Nonheme iron; requires ATP for catalysis. |
| Cellular location | Cytoplasm; in some organisms, also associated with membranes or nuclei. |
| Pathological relevance | Target of anticancer and antiviral drugs; involved in replication stress and cancer progression. |
What Is GO:0005971?
The ribonucleoside-diphosphate reductase complex is an enzyme complex composed of 2-4 or more subunits, which usually contains nonheme iron and requires ATP for catalysis. It catalyzes the formation of 2'-deoxyribonucleoside diphosphate from ribonucleoside diphosphate, using either thioredoxin disulfide or glutaredoxin disulfide as an acceptor. This definition is based on the QuickGO entry for GO:0005971.
Why Is ribonucleoside-diphosphate reductase complex Important in Cell Biology?
The ribonucleoside-diphosphate reductase complex is essential for the production of deoxyribonucleotides, the building blocks of DNA. Without its activity, cells cannot replicate their genomes or repair DNA damage, leading to cell cycle arrest and apoptosis. Because of this central role, the complex is a major target for chemotherapeutic agents such as gemcitabine, which inhibit RNR and induce replication stress in cancer cells. Moreover, dysregulation of RNR subunits is associated with cancer progression, and targeting RNR has shown efficacy in preclinical models of pancreatic cancer and Ewing sarcoma. Thus, studying this complex provides insights into fundamental DNA metabolism and offers opportunities for therapeutic intervention.
• Essential for DNA replication and repair by supplying dNTPs.
• Rate-limiting step in de novo dNTP synthesis.
• Target of nucleoside analog drugs like gemcitabine.
• Involved in replication stress and cancer cell survival.
• Subunit B1 (nrdA) and B2 (nrdB) form active and inactive complexes regulated by ATP and iron.
• Mutations in RNR subunits can alter enzyme activity and drug sensitivity.
• RNR inhibition synergizes with other therapies in pancreatic cancer and Ewing sarcoma.
• Bacteriophage T4 RNR serves as a model for understanding subunit interactions and allosteric regulation.
• RNR activity is cell cycle-regulated, peaking during S phase.
• CRISPR screens have identified RNR subunits as vulnerabilities in multiple cancer types.
Structure and Composition of ribonucleoside-diphosphate reductase complex
Subunit Architecture
In simple terms: The RNR complex is built from two main types of protein subunits that work together to convert ribonucleotides to deoxyribonucleotides.
The ribonucleoside-diphosphate reductase complex typically consists of two large subunits (B1, encoded by nrdA in bacteriophage T4 and RRM1 in humans) and two small subunits (B2, encoded by nrdB in T4 and RRM2 in humans), forming an α2β2 holoenzyme. The large subunit contains the catalytic site and allosteric regulatory sites, while the small subunit houses a diferric iron center and a tyrosyl radical essential for catalysis. In bacteriophage T4, proteins B1 and B2 can form active and inactive complexes depending on environmental conditions, illustrating dynamic assembly.
Active and Inactive Complexes
In simple terms: The RNR subunits can assemble into either active or inactive forms, and the cell controls this balance to regulate enzyme activity.
Studies on bacteriophage T4 RNR have shown that proteins B1 and B2 form active complexes under reducing conditions, while oxidative conditions promote inactive complexes. The formation of active and inactive complexes is a key regulatory mechanism that allows rapid modulation of RNR activity in response to cellular redox state and nucleotide pools. In mammalian cells, the RNR holoenzyme is also regulated by subunit stoichiometry and post-translational modifications.
Iron Center and Radical Formation
In simple terms: The small subunit contains an iron center that generates a stable radical, which is required for the enzyme to perform its chemical reaction.
The small subunit (B2/RRM2) contains a nonheme diferric iron center that, together with a tyrosyl radical, is essential for catalysis. The iron center is assembled by a complex process involving iron chaperones and requires oxygen. The tyrosyl radical is generated by the reaction of the diferrous center with oxygen, and it is stabilized by the protein environment. This radical is transferred to the active site in the large subunit to initiate the reduction of the ribose ring.
Allosteric Regulation by ATP
In simple terms: ATP and other nucleotides bind to the large subunit and change the enzyme's shape, controlling its activity and substrate specificity.
The large subunit (B1/RRM1) contains allosteric sites that bind ATP, dATP, dTTP, and dGTP, which regulate overall activity and substrate specificity. ATP binding activates the enzyme, while dATP inhibits it, providing feedback control based on cellular dNTP levels. This allosteric regulation ensures balanced dNTP pools for DNA replication and repair. The binding of ATP also promotes the formation of the active α2β2 complex.
Key Genes Involved in GO:0005971 ribonucleoside-diphosphate reductase complex
The following genes and proteins are key components or regulators of the ribonucleoside-diphosphate reductase complex across species.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RRM1 | Large subunit of human RNR; contains catalytic and allosteric sites | Target of gemcitabine; biomarker for drug response |
| RRM2 | Small subunit of human RNR; contains iron center and tyrosyl radical | Overexpressed in cancers; target for inhibition |
| RRM2B | p53-inducible small subunit; involved in mitochondrial DNA synthesis | Regulates dNTP pools for mitochondrial DNA |
| nrdA | Bacteriophage T4 large subunit (B1) | Model for subunit interactions and allosteric regulation |
| nrdB | Bacteriophage T4 small subunit (B2) | Model for radical generation and iron center assembly |
| TRX | Thioredoxin; reduces disulfide in RNR catalytic cycle | Provides reducing equivalents for RNR |
| GRX | Glutaredoxin; alternative reductant for RNR | Maintains RNR activity under oxidative stress |
| ATP | Allosteric activator of RNR | Required for catalysis and complex assembly |
| dATP | Allosteric inhibitor of RNR | Feedback regulation of dNTP pools |
| FACT | Chromatin remodeler; interacts with RRM2 | Dual inhibition with RRM2 in pancreatic cancer |
| HDAC | Histone deacetylase; regulates RNR subunit expression | HDAC inhibitors target RNR in Ewing sarcoma |
| p53 | Transcription factor; induces RRM2B | Links DNA damage to dNTP supply |
| E2F | Transcription factor; regulates RRM1 and RRM2 | Controls cell cycle-dependent RNR expression |
| Cdc25 | Phosphatase; regulates cell cycle progression | Indirectly affects RNR activity |
| Akt | Kinase; promotes RRM2 expression | Survival signaling linked to RNR |
| mTOR | Kinase; regulates translation of RNR subunits | Growth factor signaling controls RNR |
| MYC | Oncogene; drives RRM2 expression | MYC-driven cancers depend on RNR |
| KRAS | Oncogene; upregulates RNR subunits | Pancreatic cancer with KRAS mutation relies on RNR |
How Is ribonucleoside-diphosphate reductase complex Regulated?
The ribonucleoside-diphosphate reductase complex is regulated at multiple levels. Allosteric regulation by ATP and dATP controls overall activity and substrate specificity. Transcriptional regulation by E2F and p53 adjusts subunit levels during the cell cycle and in response to DNA damage. Post-translational modifications, including phosphorylation and ubiquitination, affect subunit stability and complex assembly. In cancer, oncogenic signaling through MYC, KRAS, and Akt upregulates RRM2, contributing to increased dNTP pools and replication stress. HDAC inhibitors can downregulate RNR subunits, leading to replication stress in Ewing sarcoma cells.
ribonucleoside-diphosphate reductase complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RRM2 | Pancreatic ductal adenocarcinoma | Knockout or knockdown in pancreatic cancer cell lines |
| RRM2 | Ewing sarcoma | HDAC inhibitor treatment combined with RRM2 knockout |
| RRM1 | Non-small cell lung cancer | Overexpression or point mutation to study gemcitabine resistance |
| RRM2B | Mitochondrial DNA depletion syndrome | Knock-in of patient mutations in cell lines |
| nrdA/nrdB | Bacteriophage T4 model | Site-directed mutagenesis to study subunit interactions |
Cancer
The ribonucleoside-diphosphate reductase complex is a validated target in cancer therapy. Gemcitabine, a nucleoside analog, inhibits RNR and is used in pancreatic cancer and other malignancies. Dual inhibition of FACT and RRM2 suppresses pancreatic ductal adenocarcinoma driven by oncohistone H2BG53D, highlighting the therapeutic potential of targeting RNR in specific cancer contexts. In Ewing sarcoma, HDAC inhibitors downregulate DNA replication regulators, including RNR subunits, and induce replication stress. Overexpression of RRM2 is associated with poor prognosis and chemoresistance in multiple cancers.
Replication Stress and Genome Instability
Inhibition or loss of RNR activity leads to depleted dNTP pools, causing replication fork stalling and DNA damage. This replication stress can activate the DNA damage response and induce cell cycle arrest or apoptosis. Cancer cells with high proliferation rates are particularly sensitive to RNR inhibition, making it an attractive target for combination therapies.
Mitochondrial DNA Depletion Syndromes
The p53-inducible small subunit RRM2B is critical for mitochondrial DNA synthesis, and mutations in RRM2B cause mitochondrial DNA depletion syndromes. This highlights the importance of RNR in maintaining mitochondrial genome integrity.
From ribonucleoside-diphosphate reductase complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does RRM2 knockout inhibit tumor growth? | CRISPR knockout in cancer cell lines and xenografts |
| How do point mutations in RRM1 affect drug binding? | CRISPR point mutation knock-in in cell lines |
| What is the effect of RRM2 overexpression on dNTP pools? | CRISPR overexpression (CRISPRa) or lentiviral overexpression |
| How do RNR subunits assemble into active complexes? | Tagged knock-in (e.g., GFP) for live-cell imaging |
| What is the role of RRM2B in mitochondrial DNA maintenance? | Knockout and rescue with wild-type or mutant RRM2B |
| Can dual targeting of FACT and RRM2 suppress pancreatic cancer? | Combined CRISPR knockout and pharmacological inhibition |
How to Study the ribonucleoside-diphosphate reductase complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression levels | Quantify RRM1/RRM2 mRNA in cancer cells |
| Ribo-seq | Translation efficiency | Measure RNR subunit translation under stress |
| Western blot | Protein abundance and modifications | Assess RNR subunit levels after drug treatment |
| Immunoprecipitation | Protein-protein interactions | Detect B1-B2 complex formation |
| Enzyme activity assay | Catalytic conversion of ribonucleotides | Measure RNR activity in vitro |
| CRISPR knockout screen | Gene essentiality and synthetic lethality | Identify genes that synergize with RNR inhibition |
| Flow cytometry | Cell cycle and apoptosis | Evaluate replication stress after RNR knockdown |
| Live-cell imaging | Subcellular localization and dynamics | Track tagged RNR subunits in real time |
Genomic and Transcriptomic Profiling
RNA-seq and Ribo-seq can quantify expression of RNR subunits and measure translation efficiency under different conditions. CRISPR screens coupled with RNA-seq can identify genes that synergize with RNR inhibition.
Proteomic and Biochemical Assays
Western blotting, immunoprecipitation, and mass spectrometry can assess RNR subunit levels, complex formation, and post-translational modifications. Enzyme activity assays using radiolabeled substrates measure RNR catalytic activity.
Imaging and Flow Cytometry
Fluorescence microscopy with tagged RNR subunits can visualize complex localization and assembly in live cells. Flow cytometry can measure cell cycle arrest and apoptosis following RNR inhibition.
CRISPR-Based Functional Genomics
Genome-wide CRISPR knockout screens can identify synthetic lethal interactions with RNR subunits. Base editing and prime editing enable precise point mutations to study drug resistance.
How CRISPR Can Be Used to Study GO:0005971 ribonucleoside-diphosphate reductase complex
Knockout
CRISPR knockout of RRM1 or RRM2 depletes RNR activity, leading to dNTP starvation, replication stress, and cell cycle arrest. Knockout cell lines are valuable for studying the consequences of RNR loss and for identifying compensatory pathways.
Point Mutation
CRISPR point mutation knock-in can introduce specific amino acid changes in RRM1 or RRM2 to study drug resistance, allosteric regulation, or catalytic mechanism. For example, mutations in the allosteric site can alter ATP/dATP sensitivity.
Knock-in
Tagged knock-in of RNR subunits (e.g., GFP or HA) allows visualization and purification of native complexes for biochemical and imaging studies. Knock-in of patient-derived mutations in RRM2B can model mitochondrial DNA depletion syndromes.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of RRM2 increases dNTP pools and can promote tumorigenesis or drug resistance. Overexpression models are useful for studying the oncogenic potential of RNR subunits.
How EDITGENE Supports ribonucleoside-diphosphate reductase complex Research
Researchers studying ribonucleoside-diphosphate reductase complex-related genes often need to determine whether a candidate gene is causally involved in dNTP metabolism, replication stress, or drug response. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for ribonucleoside-diphosphate reductase complex research.
Frequently Asked Questions About ribonucleoside-diphosphate reductase complex
What is the ribonucleoside-diphosphate reductase complex?
It is an enzyme complex (GO:0005971) that converts ribonucleoside diphosphates to 2'-deoxyribonucleoside diphosphates, essential for DNA synthesis.
What genes are involved in the ribonucleoside-diphosphate reductase complex?
Key genes include RRM1, RRM2, and RRM2B in humans, and nrdA and nrdB in bacteriophage T4.
What is the function of GO:0005971?
GO:0005971 describes the cellular component that catalyzes the formation of deoxyribonucleotides, required for DNA replication and repair.
How is the ribonucleoside-diphosphate reductase complex regulated?
It is regulated allosterically by ATP and dATP, transcriptionally by E2F and p53, and post-translationally by phosphorylation.
What diseases are associated with RNR complex dysfunction?
Cancer, replication stress, and mitochondrial DNA depletion syndromes are linked to RNR dysfunction.
What drugs target the ribonucleoside-diphosphate reductase complex?
Gemcitabine and other nucleoside analogs inhibit RNR and are used in cancer therapy.
How can CRISPR be used to study the RNR complex?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of RNR subunit function.
What is the role of RRM2 in cancer?
RRM2 is often overexpressed in cancers, supports high dNTP demand, and is a target for inhibition.
What is the difference between RRM1 and RRM2?
RRM1 is the large catalytic subunit, while RRM2 is the small subunit containing the iron center and tyrosyl radical.
How does the RNR complex contribute to DNA replication?
By supplying dNTPs, it ensures that DNA polymerases have the building blocks needed for genome duplication.
Conclusion
The ribonucleoside-diphosphate reductase complex (GO:0005971) is a central enzyme in DNA metabolism, converting ribonucleotides to deoxyribonucleotides and thus supporting genome replication and repair. Its multi-subunit architecture, iron center, and allosteric regulation make it a fascinating subject for structural and mechanistic studies. Clinically, the complex is a proven target for anticancer and antiviral drugs, and ongoing research continues to uncover its roles in replication stress, cancer progression, and mitochondrial DNA maintenance. CRISPR-based models are invaluable for dissecting these functions and for identifying new therapeutic strategies.
References
- 1. Mini E et al.. 2006. Cellular pharmacology of gemcitabine.. Ann Oncol 17 Suppl 5:v7-12 PMID: 16807468
- 2. Qin T et al.. 2025. Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohistone H2BG53D.. Cell Rep 44(12):116596 PMID: 41284383
- 3. Erickson HK. 2001. Kinetics in the pre-steady state of the formation of cystines in ribonucleoside diphosphate reductase: evidence for an asymmetric complex.. Biochemistry 40(32):9631-7 PMID: 11583163
- 4. Ikenaka K et al.. 1981. Possible regulation of ribonucleoside diphosphate reductase.. Gan 72(1):8-18 PMID: 7024035
- 5. Berglund O. 1975. Ribonucleoside diphosphate reductase induced by bacteriophage T4. III. Isolation and characterization of proteins B1 and B2.. J Biol Chem 250(18):7450-5 PMID: 809436
- 6. Koppenhafer SL et al.. 2025. Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells.. Cancer Res Commun 5(6):1034-1048 PMID: 40478628
- 7. Brown NC et al.. 1969. Ribonucleoside diphosphate reductase. Formation of active and inactive complexes of proteins B1 and B2.. J Mol Biol 46(1):25-38 PMID: 4902211
- 8. Cook KS et al.. 1983. Properties of Bacteriophage T4 ribonucleoside diphosphate reductase subunits coded by nrdA and nrdB mutants.. J Biol Chem 258(10):6064-72 PMID: 6343369
